Total Payments
$45,851
2024 Payments
$175.76
Companies
20
Transactions
85
Medicare Patients
695
Medicare Billing
$88,301
Payment Breakdown by Category
Research$37,413 (81.6%)
Travel$5,164 (11.3%)
Food & Beverage$3,261 (7.1%)
Education$12.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37,413 | 6 | 81.6% |
| Travel and Lodging | $5,164 | 18 | 11.3% |
| Food and Beverage | $3,261 | 59 | 7.1% |
| Education | $12.50 | 2 | 0.0% |
Payments by Type
Research
$37,413
6 transactions
General
$8,438
79 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $39,614 | 14 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $1,966 | 12 | $0 (2018) |
| Janssen Research & Development, LLC | $1,376 | 10 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $1,107 | 6 | $0 (2018) |
| Ironwood Pharmaceuticals, Inc | $505.41 | 3 | $0 (2018) |
| Purdue Pharma L.P. | $315.40 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $260.10 | 4 | $0 (2024) |
| Abbott Laboratories | $244.97 | 13 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $125.39 | 3 | $0 (2018) |
| Kowa Pharmaceuticals America, Inc. | $113.68 | 6 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $175.76 | 9 | Abbott Laboratories ($58.57) |
| 2023 | $266.77 | 10 | GlaxoSmithKline, LLC. ($111.89) |
| 2022 | $109.02 | 6 | Abbott Laboratories ($65.87) |
| 2021 | $252.04 | 8 | GlaxoSmithKline, LLC. ($119.29) |
| 2020 | $17.53 | 1 | Kowa Pharmaceuticals America, Inc. ($17.53) |
| 2019 | $6,168 | 1 | Eli Lilly and Company ($6,168) |
| 2018 | $19,766 | 34 | Eli Lilly and Company ($16,091) |
| 2017 | $19,095 | 16 | Eli Lilly and Company ($17,355) |
All Payment Transactions
85 individual payment records from CMS Open Payments — Page 2 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug) | Food and Beverage | Cash or cash equivalent | $13.63 | General |
| Category: Cardiovascular | ||||||
| 12/09/2021 | Abbott Laboratories | FreeStyle Libre 2 (Device) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Diabetes Care | ||||||
| 12/01/2021 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $119.29 | General |
| Category: RESPIRATORY | ||||||
| 09/27/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug) | Food and Beverage | Cash or cash equivalent | $15.35 | General |
| Category: Cardiovascular | ||||||
| 08/09/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $25.26 | General |
| Category: Cardiovascular | ||||||
| 05/14/2021 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $23.74 | General |
| Category: Cardiovascular | ||||||
| 03/21/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: NEUROSCIENCE | ||||||
| 02/01/2021 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Cardiovascular | ||||||
| 09/09/2020 | Kowa Pharmaceuticals America, Inc. | Livalo (Drug), Bystolic | Food and Beverage | Cash or cash equivalent | $17.53 | General |
| Category: Cardiovascular | ||||||
| 01/07/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $6,168.00 | Research |
| Study: A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | ||||||
| 12/06/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Education | In-kind items and services | $6.25 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/08/2018 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Education | In-kind items and services | $6.25 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/24/2018 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $2.94 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/16/2018 | AstraZeneca Pharmaceuticals LP | BRILINTA (Drug) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/24/2018 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: RESPIRATORY | ||||||
| 07/24/2018 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Food and Beverage | In-kind items and services | $48.32 | General |
| Category: RESPIRATORY | ||||||
| 07/24/2018 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Travel and Lodging | In-kind items and services | $39.88 | General |
| Category: RESPIRATORY | ||||||
| 07/24/2018 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: RESPIRATORY | ||||||
| 07/23/2018 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Travel and Lodging | In-kind items and services | $738.78 | General |
| Category: RESPIRATORY | ||||||
| 07/23/2018 | Merck Sharp & Dohme Corporation | MK-7264 (Drug) | Travel and Lodging | In-kind items and services | $189.75 | General |
| Category: RESPIRATORY | ||||||
| 06/23/2018 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug) | Food and Beverage | In-kind items and services | $277.36 | General |
| Category: Gastroenterology | ||||||
| 06/23/2018 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug) | Travel and Lodging | In-kind items and services | $143.62 | General |
| Category: Gastroenterology | ||||||
| 06/23/2018 | Ironwood Pharmaceuticals, Inc | LINZESS (Drug) | Travel and Lodging | In-kind items and services | $84.43 | General |
| Category: Gastroenterology | ||||||
| 05/19/2018 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 05/19/2018 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $35.03 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3298176 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $25,840 | 2 |
| A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA | Eli Lilly and Company | $6,187 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $5,311 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP, PHASE 2 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS -SLE | Eli Lilly and Company | $74.85 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 130 | 235 | $25,974 | $16,459 |
| 2022 | 7 | 174 | 297 | $32,224 | $21,271 |
| 2021 | 6 | 170 | 304 | $36,575 | $25,788 |
| 2020 | 5 | 221 | 381 | $43,627 | $24,784 |
Total Patients
695
Total Services
1,217
Medicare Billing
$88,301
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 40 | 113 | $16,558 | $9,902 | 59.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 23 | 23 | $3,410 | $3,111 | 91.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 32 | $3,168 | $1,809 | 57.1% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 12 | 12 | $1,800 | $1,003 | 55.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 21 | 39 | $589.76 | $327.60 | 55.5% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 16 | 16 | $448.00 | $305.28 | 68.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 144 | $20,878 | $12,931 | 61.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 31 | 31 | $4,523 | $4,274 | 94.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 18 | 34 | $3,366 | $2,184 | 64.9% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 11 | 11 | $1,650 | $953.69 | 57.8% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 34 | 34 | $952.00 | $658.13 | 69.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 13 | 15 | $435.00 | $187.18 | 43.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 18 | 28 | $420.00 | $83.01 | 19.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 68 | 186 | $27,212 | $18,005 | 66.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 37 | 37 | $5,439 | $5,271 | 96.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 28 | $2,772 | $1,989 | 71.8% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 18 | 21 | $609.00 | $243.28 | 39.9% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 11 | 11 | $308.00 | $216.59 | 70.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 13 | 21 | $235.00 | $63.00 | 26.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 76 | 198 | $28,953 | $15,623 | 54.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 44 | 44 | $6,497 | $5,497 | 84.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 50 | 69 | $6,851 | $3,117 | 45.5% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 28 | 33 | $936.29 | $437.76 | 46.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 23 | 37 | $389.52 | $110.34 | 28.3% |
About Dr. Francisco Miranda, MD
Dr. Francisco Miranda, MD is a Internal Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2005. The National Provider Identifier (NPI) number assigned to this provider is 1023005204.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Francisco Miranda, MD has received a total of $45,851 in payments from pharmaceutical and medical device companies, with $175.76 received in 2024. These payments were reported across 85 transactions from 20 companies. The most common payment nature is "" ($37,413).
As a Medicare-enrolled provider, Miranda has provided services to 695 Medicare beneficiaries, totaling 1,217 services with total Medicare billing of $88,301. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Miami, FL
- Active Since 10/03/2005
- Last Updated 12/04/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1023005204
Products in Payments
- TRULICITY (Drug) $6,348
- MK-7264 (Drug) $1,107
- CNP520 (Drug) $1,031
- LINZESS (Drug) $505.41
- TRELEGY ELLIPTA (Drug) $148.21
- ENTRESTO (Drug) $129.22
- XARELTO (Drug) $125.39
- FREESTYLE LIBRE 3 (Device) $119.48
- Livalo (Drug) $113.68
- FREESTYLE LIBRE 2 (Device) $106.97
- QUVIVIQ (Drug) $39.95
- Veozah (Drug) $31.74
- STRENSIQ (Biological) $24.98
- UBRELVY (Drug) $21.91
- ELIQUIS (Drug) $20.10
- FreeStyle Libre 2 (Device) $18.52
- SHINGRIX (Biological) $18.51
- BRILINTA (Drug) $17.18
- MOUNJARO (Drug) $15.33
- Vascepa (Drug) $14.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Miami
Jay Skyler, Md, MD
Internal Medicine — Payments: $2.9M
Internal Medicine $2.9M
Dr. Lukasz Kwapisz
Internal Medicine — Payments: $800,664
Internal Medicine $800,664
Mark Kutner, Md, MD
Internal Medicine — Payments: $610,516
Internal Medicine $610,516
Dr. Ian Del Conde Pozzi, M.d, M.D
Internal Medicine — Payments: $499,756
Internal Medicine $499,756
Mr. Angel Carrasco, M.d, M.D
Internal Medicine — Payments: $493,362
Internal Medicine $493,362
Dr. Edward Mezerhane, Md, MD
Internal Medicine — Payments: $470,504
Internal Medicine $470,504